Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy

Josie Carmichael¹, Hassan Fadavi², Fukashi Ishibashi³, Angela C. Shore¹ and Mitra Tavakoli¹∗

¹ Diabetes and Vascular Research Centre, National Institute for Health Research, Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, United Kingdom, ² Peripheral Neuropathy Group, Imperial College, London, United Kingdom, ³ Internal Medicine, Ishibashi Medical and Diabetes Centre, Hiroshima, Japan

The incidence of both type 1 and type 2 diabetes is increasing worldwide. Diabetic peripheral neuropathy (DPN) is among the most distressing and costly of all the chronic complications of diabetes and is a cause of significant disability and poor quality of life. This incurs a significant burden on health care costs and society, especially as these young people enter their peak working and earning capacity at the time when diabetes-related complications most often first occur. DPN is often asymptomatic during the early stages; however, once symptoms and overt deficits have developed, it cannot be reversed. Therefore, early diagnosis and timely intervention are essential to prevent the development and progression of diabetic neuropathy. The diagnosis of DPN, the determination of the global prevalence, and incidence rates of DPN remain challenging. The opinions vary about the effectiveness of the expansion of screenings to enable early diagnosis and treatment initiation before disease onset and progression. Although research has evolved over the years, DPN still represents an enormous burden for clinicians and health systems worldwide due to its difficult diagnosis, high costs related to treatment, and the multidisciplinary approach required for effective management. Therefore, there is an unmet need for reliable surrogate biomarkers to monitor the onset and progression of early neuropathic changes in DPN and facilitate drug discovery. In this review paper, the aim was to assess the currently available tests for DPN’s sensitivity and performance.

Keywords: microvascular complications, Diabetic Neuropathy, Screening, Diagnosis, Early Detection, neuropathy biomarkers

INTRODUCTION

Diabetes is one of the fastest-growing health challenges of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years (1). The International Diabetes Federation reported that in 2019, the prevalence of diabetes was 9.3% (463 million people worldwide) with a predicted rise to 10.9% (700 million people) by 2045 (2). Furthermore, it has been shown that over 1.1 million children and adolescents below 20 years have type 1 diabetes. On top of
these staggering figures, are the number of people with impaired glucose tolerance (IGT) or metabolic syndrome with 373.9 million in 2019 (7.5%) and predicted rise to 548.4 million (8.6%) by 2045 (2).

In the UK alone, there were 4.8 million people with diabetes in 2019. Diabetes is on the rise. Figures from Diabetes UK shows that someone is diagnosed with diabetes every two minutes, with 5.3 million expected to be living with the condition by 2025 (3).

Diabetes is strongly associated with both microvascular and macrovascular complications. As a result, 10% of global health expenditure, equal to USD 760 billion, is directed toward diabetes and its complications (2). Microvascular changes lead to nephropathy, retinopathy and neuropathy. Among these complications, diabetic peripheral neuropathy (DPN) is the most common and costly diabetes-associated complication, occurring in around 50% of individuals with diabetes (4). Distal symmetric polyneuropathy (DSPN) (5) typically follows a distal-proximal course and results in symmetrical symptoms and signs between the body’s left and right sides. Common symptoms include burning, numbness, tingling, pain and/or weakness starting in the distal lower extremities which progress into more extreme symptoms of neuropathic pain in around 10-30% of affected patients (6, 7). Symptoms may be sporadic or constant but can be debilitating and in many people lead to depression, sleep disorders and overall reduced quality of life (8).

The true prevalence of DPN is underestimated as its assessment is challenging. However, DPN is recognized as the most common complication of diabetes.

DPN is the strongest initiating risk factor for diabetic foot ulceration (neuropathic ulcer) (9, 10), and existing ulcers may be further exacerbated from damage to sensory neurons. Resultant limb numbness causes ulcers to remain undetected for longer periods (10); thus, corrective actions are not taken nor advice sought at early stages of the disease. Often the first sign that a person has diabetic peripheral neuropathy (DPN) is a foot ulcer, which may lead to irreversible tissue damage, lower limb amputation and significant morbidity.

In the UK, people with diabetes account for more than 40% of hospitalizations for major amputations and 73% of emergency admissions for minor amputations. A single diabetes related foot ulcer can take over 240 days to put into remission and costs £8,000 pa to treat. Ulcers frequently recur and eventually may require the amputation of a lower limb. DPN is hugely costly to our NHS (>£1.1 billion pa in direct medical costs) and to the wider UK economy (~£4 billion), is particularly debilitating and distressing for patients and their families and can lead to an untimely death (11, 12), with five-year mortality ranging from 52 to 80 percent after major amputation (13).

Furthermore, with diabetes related lower limb amputations increasing at the rate of almost 20% per annum in line with the increasing prevalence of diabetes, there is a huge strain on NHS budgets which are unable to keep up.

Autonomic neuropathies are a class of DPN which share similar diffuse pathophysiology with DSPN, but differ by being largely non-sensory (4). These typically affect the cardiovascular, urogenital and gastrointestinal systems. Patients may also suffer from sudomotor dysfunction, hypoglycemia obliviousness, and abnormal pupillary function (5). Rare forms of DPN include mononeuropathies,polyradiculopathies and treatment-induced neuropathies (5). These atypical forms are generally self-limiting and resolve with medical management and physical therapy, usually over several months (11).

In clinical settings, there are several different approaches to assess diabetic peripheral neuropathy (DPN), and the choice of the test will depend on the aim of testing. It is usually sufficient in a busy clinic to establish whether a patient is symptomatic, particularly of painful DPN (12), and whether or not they are at high risk of foot ulceration typically through monofilament testing. However, to fully assess damage and phenotype of DPN, sensory deficits must be detected early. Those accurate biomarkers are available for monitoring of DPN and for use in clinical trials of potential new treatments.

Currently, there are no simple markers for early detection of DPN in routine clinical practice. The measures we use are crude and detect the disease very late in its natural history. Even the benefits gained by standardizing clinical assessment with scored clinical evaluations remain subjective, heavily reliant on the examiners’ interpretations.

This paper reviews the current knowledge and the optimal approaches for diagnosis and screening of diabetic peripheral neuropathy.

**TYPES OF NERVE FIBERS**

Peripheral nerve fibers can be classified using Erlanger and Gasser’s classification, which defines nerves based on diameter, conduction speed, and myelination level (Table 1). A-fibers have the largest diameter, with the thickest myelination and fastest conduction speed, and act as sensory and motor fibers within the somatic nervous system. They may be further divided into large nerve fibers that have sensory and motor functions (Aδ and Aβ), and small nerve fibers (Aγ which has motor functions, and Aδ which may be autonomic or sensory fibers) (14).

Group B-fibers are small, with moderate myelination and slower conduction velocities than A-fibers. B-fibers act mainly as general visceral afferent and pre-ganglionic fibers and are found only in the autonomic nervous system.

Group C-fibers have a small diameter, low conduction velocity and are the only unmyelinated group. They act as somatic, afferent fibers that carry sensory information relating to temperature and pain, as well as having autonomic functions such as the stimulation of the sweat glands (14).

**Epidemiology**

The prevalence of diabetic peripheral neuropathy (DPN) reported in various studies ranges from 6% to 51% depending on the population (15, 16). In the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DDCT/EDIC) Study, the prevalence of DPN in adults with type 1 diabetes was 6% at baseline and increased to 30% after 13–14 years of follow-up (17). The prevalence of DPN among adults with type 1 diabetes in the
Pittsburgh Epidemiology of Diabetes Complications was 34% and increased significantly with age (18–29 years: 18%; ≥30 years: 58%). It has been estimated that half of all children with diabetes with a duration of 5 years or longer already have diabetic neuropathy (18) and nearly 25% of pediatric patients with newly diagnosed diabetes have abnormal findings on nerve conduction studies (NCS), indicating nerve damage (19).

The prevalence of DPN is somewhat higher in patients with T2DM when compared to T1DM (4). The ‘Action to Control Cardiovascular Risk in Diabetes’ (ACCORD) (20) trial and the ‘Veteran Affairs Diabetes Trial’ (21) found that DPN was present in 42% and 39% of adults with type 2 diabetes, respectively, at baseline measurement. A study comparing magnetic resonance imaging (MRI) scans of the sciatic nerve in T1DM, and T2DM patients with DPN found that the predominant type of nerve lesion differed between the two (22). This study found that in T1DM, lesions were predominantly associated with poor glycemic control and loss of nerve conduction, whereas in T2DM lesions were associated with changes in lipid metabolism. This raises the question of whether damage to peripheral nerves results in different patterns of nerve damage, and thus would require different types of preventive treatment.

**Risk Factors**

In both main types of diabetes, the prevalence and severity of DPN increases with disease duration and increasing age (16). A large study of 1172 patients with diabetes assessed for neuropathy at baseline reported that patients who had developed neuropathy by roughly ten-year follow-up were on average 3.8 years older and had diabetes for 3.3 years longer at baseline (16). Furthermore, the study found that in both T1DM and T2DM, higher hemoglobin A1c (HbA1c) level was a significant predictor of the development of diabetic neuropathy (16).

In cohorts of patients with T2DM, several metabolic syndromes such as hypertension, abdominal obesity, lower high-density lipoprotein (HDL) levels and hypertriglyceridemia have been consistently associated with DPN development (23), with additional independent risk factors including alcohol abuse and increased height (24). In a cohort of patients with T1DM, the EURODIAB prospective complications (25) study reported similar modifiable risk factors to those identified in T2DM, explicitly having an association with raised triglyceride level, obesity, smoking and hypertension. Several genes have also been linked to an increased risk of diabetic neuropathy. Still, only ACE (encoding angiotensin-converting enzyme) and MTHFR (encoding methylenetetrahydrofolate reductase) polymorphisms have been confirmed using large patient cohorts in multiple populations (24). Research into the role of genetics in diabetic neuropathy is currently limited, and many more studies are required.

Significantly lower levels of clinical neuropathy in South Asian patients have been reported compared to Europeans and Afro-Caribbean (26). A recent study found that in a population of people with type 2 diabetes, South Asians had significantly better-preserved small nerve fiber integrity than equivalent Europeans (27). However, this patient cohort was recruited from primary care, and most patients had no or mild neuropathy, so it was not representative of the diabetic population overall. A proposed explanation for the reduced risk was the differences in the transcutaneous partial pressure of oxygen (TCpO2) and height between the ethnicities (27). However, the study suggesting this explanation did not adjust for a range of possible confounders such as obesity, and alcohol intake, between ethnicities, all of which are established risk factors for developing DPN. A more recent study suggested that the variation may be due to differences in height and adiposity between the ethnic groups, as the adjustment for these factors rendered the difference insignificant (28).

**Prevention/Treatment**

There is currently no Food and Drug Administration (FDA) approved therapy to prevent or reverse human DPN (4). The current management approach focuses on reasonable glycemic control, lifestyle modifications, and management of associated pain. The reasonable glycemic control consists of not only strict HbA1c control but also reduced glycemic variability, because glycemic variability has recently emerged as an another measure of glycemic control, which might constitute an additive, or even better predictor of microvascular complications including neuropathy than mean HbA1c levels (29, 30).

Previous studies have found that improving HbA1c levels does affect DPN progression in patients with T2DM (20, 31). The ACCORD study (20) found that intensive treatment caused delay in onset of albuminuria and it reduced neuropathy, MNSI socre, loss of ankle jerks, loss of light touch at end of the study. The veteranes study (31) assessed whether new evidence of clinical neuropathy occurred during the period of intensive versus normal control and had quite severe criteria for definitions. The Epidemiology of Diabetes Interventions and Complications (EDIC) trial reported that intensive glucose control significantly delayed the development and progression of diabetic neuropathy in T1DM patients over time (17).

**TABLE 1 | Classification of nerve fibers in the peripheral nervous system according to modified Erlanger and Gasser.**

| Classification | Myelination | Diameter (um) | Conduction Velocity (m/s) | Type | Function |
|----------------|-------------|---------------|----------------------------|------|----------|
| Aα (alpha)     | Yes         | 12-22         | 70-120                     | Sensory/motor | Proprioception, touch sensory, somatic motor to extrafusal muscles |
| Aβ (beta)      | Yes         | 5-12          | 30-70                      | Sensory/motor | Proprioception, touch/pressure sensory, somatic motor to intrafusal muscles |
| Aδ (delta)     | Yes         | 1-5           | 5-30                       | Sensory | Touch and cold thermoreceptors, nociception |
| Ay (gamma)     | Yes         | 2-8           | 15-30                      | Motor | Somatic motor to intrafusal muscles |
| B               | Yes         | <3            | 3-15                       | Autonomic | Visceral afferent fibers and preganglionic efferent fibers |
| C               | No          | 0.1-1.3       | 0.6-2                      | Sensory/ autonomic | Temperature (warm receptors), pain perception, nociception, itching |

Frontiers in Endocrinology | www.frontiersin.org 3 May 2021 | Volume 12 | Article 671257
Another study, following a cohort of T1DM patients over 24 years confirmed these findings. Patients who had stable, near-normal HbA1c levels (mean <7.0%) had significantly less deterioration in nerve fiber function when measured using electrophysiology and quantitative sensory methods (p<0.05 for all measures at 24 years follow-up) (32).

Attempts have been made to reduce DPN by lifestyle interventions (24). Several studies have demonstrated a potential for improved outcomes in patients with diagnosed DPN through exercise regimes put in place over ten weeks (33) to 12 months (34). Despite insignificant improvements in body mass index (BMI), these studies reported a significant improvement in objective nerve function measures and reduced neuropathy symptoms. Neither of these studies included a control group, which is essential to provide a measure of the change in neuropathy which could be expected over time without intervention but with the same amount of scrutiny, for example, additional contact time with healthcare professionals or individuals paying more attention to their health due to taking part in a study. In the absence of a control group, it is difficult to ensure that neuropathy improvements are genuinely due to modifications in exercise regimes alone.

A recent comprehensive study in Japanese patients with T2DM under poor glycemic control (HbA1c 9.6%, 81.6 mmol/mol) at baseline assessed the impact of intensive glucose control without hypoglycemia and found that normalizing A1c over the two years of follow-up resulted in significant improvement in neuropathy outcomes (35). This study also revealed that small glycemic variability assessed by SD and coefficient of variation (CV) of monthly measured HbA1c levels was associated with the improvement of neuropathy outcomes. In the follow-up study of T2DM (a median of 9.3 years), mean HbA1c levels were the main risk predictor for the composite outcome of developing or worsening diabetic neuropathy, whereas glycemic variability assessed by HbA1c variability was a better risk predictor for new incident of neuropathy (36). In the follow-up study of T1DM the long-term glycemic variability assessed by CV and SD of HbA1c levels was linked to DPN independent of mean HbA1c (37). These studies indicated that the strict HbA1c control as a long-term mean glycemic levels and suppressed glycemic variability are required for the prevention and slow neuropathy progression in patients with diabetes.

Screening
The American Diabetes Association (ADA) and the International Working Group on the Diabetic Foot (IWGDF) recommends regular examination of people with DM for the diagnosis of DPN and loss of protective sensation using simple standard tests for the identification of those at risk for diabetic foot ulcer (38, 39). It is recommended that all patients with T2DM be screened for DPN at diagnosis, and for T1DM, the screening should begin five years post-diagnosis (40). After this initial screening, all patients should be reviewed annually.

Nerve conduction studies (NCS) are considered the gold standard for the diagnosis of large fibers neuropathy. The Toronto consensus (41) recommended the use of abnormal NCS with a symptom or sign to diagnose DPN. However, the need for specialist examiners and equipment renders NCS inappropriate as a screening test. Thus, it is used only to confirm any possible/probable DN picked up post-screening using other measures (40).

More commonly, screening for DPN involves history taking for neuropathic symptoms and examination of the feet, along with a screening test (40). Traditional screening tests benefit from being quick and easy; however, like NCS, these only assess larger fiber function and are unable to detect any early changes in small nerve fibers. Furthermore, two systematic reviews focusing on the use of monofilament testing, a commonly used screening test for DPN, described a variation of diagnostic value in the current literature and a lack of consistency in recommended test procedure and interpretation (42). Sensitivity for peripheral nerve fiber damage ranged from 43-93% when using NCS as a reference standard (43). Both review papers did not recommend the sole use of monofilament testing to diagnose peripheral neuropathy (43). This is just one example of the shortcomings of current screening tests.

DIAGNOSTIC TESTS FOR DPN

While there is no single accurate definition of diabetic neuropathy, a simple definition for clinical practice is the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after excluding other causes (5). Based on this, the diagnostic tests are focused on assessing the symptoms and signs of nerve dysfunctions.

There are numerous testing methods available to assess the peripheral nervous system’s structure and function, with each test having its own advantages and disadvantages. Bedside tests used to aid diagnosis of DPN—including the 10g monofilament (Figure 1D), the Ipswich Touch Test, and vibration perception threshold testing with the Vibratip (Figure 1E), a tuning fork, or automated devices such as Neurobiothesiometer, are not only reliant on patients’ subjective response but are also mainly used to identify the loss of protective foot sensation and risk of ulceration. As such, these tests tend to diagnose DPN when it is already well established. Late diagnosis hampers the potential benefits of intensified multifactorial intervention at an early stage of the disease, which could prevent the sequelae of DPN. Unfortunately, by the time DPN is detected with the crude tests currently used, it is often very well established and consequently impossible to reverse or halt the inexorable neuropathic process. Early diagnosis and timely intervention are thus essential in preventing the development of DPN.

Some of the most common tests and methods for diagnosis of DN have been summarized in Table 2.

Symptoms
Various clinical scoring systems are available for DPN screening which involve symptom scoring, sign scoring or both (Table 3). These systems may enhance diagnostic accuracy through a composite score of different combined tests and are useful tools for aiding diagnosis of DPN, along with quantitative measures. Each questionnaire has a scoring system which can
diagnose, and in some, stratify disease severity. Table 3 presents a summary of the most commonly used questionnaires for assessing DPN.

The Neurological Symptom Score (NSS) is a 17 question, interview-based assessment of sensory, motor, and autonomic function used to screen DPN (87). Still, it is considered too extensive to be used efficiently in clinical practice. The diabetic neuropathy score (DNS) is an adaptation of the NSS that is a much quicker screening method, with only four questions and still offering moderate sensitivity (79%) and specificity (78%), but with slightly lower reliability for diagnosing DPN (45) when using a diagnostic score of 1 or more.

Other symptom scoring systems focus only on pain and differentiating neuropathic from other causes. Clinicians commonly recognize pain descriptors that are used by patients with neuropathic pain. The McGill pain questionnaire was the first questionnaire designed to offer a multidimensional assessment of pain, which included assessing severity or intensity, emotional impact, and significance to the pain sufferer (88). This questionnaire is one of the most commonly used multi-dimensional pain scales globally. A short-form is available for use in screening which has shown good agreement with the original version (89).

**Signs**

The Neuropathy disability score (NDS) is a commonly used clinical examination method that assesses neuropathy signs (Figure 1A). Thirty-five items are used for both sides, evaluating cranial nerve damage, muscle strength, sensation loss and reflex delay/loss (90). However, some of the items have demonstrated a weak relation to DPN, and the full scoring system is too long to be used in clinical practice. Therefore a revised NDS has been created. This system is more commonly used and tests for four main neuropathy signs; ankle reflex, vibration, pinprick and temperature sensation at both sides of the largest toes. A maximum score is 10, and usually, more than 6 is considered abnormal (91).

**Composite Scoring Systems**

The reliance on symptoms or signs alone may lead to low diagnostic accuracy for the presence of DPN, and a combination of both allows a more thorough assessment. Several scoring systems assess both signs and symptoms of DPN to produce a composite score. The Toronto clinical neuropathy score (TCNS) consists of three parts: symptom scores, reflex test scores and sensory test scores. The maximum score is 19, and the test is able to stratify patients into no DPN, mild DPN, moderate DPN and severe DPN depending on the overall score (92). Testing has proven validity and reliability for diagnosing and staging DPN compared to electrophysiology measures (92).

The Michigan neuropathy screening instrument (MNSI) is another commonly used composite scoring system that includes a questionnaire and a foot examination (77). Neuropathy can be defined as seven or more positive responses to this symptoms...
section alone (77). The foot examination is more frequently used and encompasses foot appearance (including ulcers), ankle reflex and the 128-Hz tuning fork test (77). One study (93) found a range of sensitivity (35-79%) and specificity (65-94%) in comparison to NCS depending on the cut-off value used for abnormality in MNSI. The higher specificity values indicate a potential high diagnostic impact for MNSI scoring; however, the lower sensitivity range indicates that milder DPN cases are likely not to get picked up.

Scoring of symptoms and signs is convenient and easy to perform as a method of screening for DPN. These tests are easily interpreted, making them a useful tool in supporting decisions on which patients should be referred on for specialist assessment. Quantitative, objective measures should be considered when the patient has signs and symptoms other than those rated by the scoring test.

### Large Fiber Tests

**Nerve Conduction Studies (NCS)**

The current ‘gold standard’ for clinical diagnosis of DPN is through nerve conduction studies (NCS) by a trained neurophysiologist (Figure 1B). In 2010, the Toronto Consensus, by an expert panel recommended that one abnormal finding as part of NCS, combined with a symptom or sign of neuropathy should be used to confirm DPN (41). NCS has also demonstrated an ability to predict future DPN (94). For reliable NCS results, close attention must be paid to factors such as filter setting, limb temperature, and recording location, as outcomes can be vulnerable to variations. Trials have demonstrated that NCS consistently demonstrate excellent intra-observer agreement (38, 95); however, a poor inter-observer agreement between expert clinical neurophysiologists is common (58) when no standardized, specific technique is followed. One study (95) assessed the results of 4 neurophysiologists, from 4 different centers. Specific assessment methods were provided in a specially prepared syllabus, and a training session was provided beforehand. The outcome was a significant improvement in inter-observer agreement with a standardized approach, and although not entirely eliminated, levels of disagreement were consequently considered clinically significant for medical practice (95).

Conversely, when considering the use of NCS in therapeutic clinical trials, even small inter-observer variability may be significant enough to impact results through impacting the statistical power of a study and thus the trial’s outcomes. This may partially explain why previous clinical trials have used NCS as a primary outcome to detect treatment efficacy and have reported failed outcomes (96–98). Evidence supports the use of a single observer to repeat electrophysiological tests on each patient in these trials.

Furthermore, Standard NCS testing is not easily applicable as a screening tool for DPN since it is time-consuming, requires a specialist operator and can be uncomfortable for the patient (58).
Electrodiagnostic studies have also been identified as one of the largest drivers of health care costs related to neuropathy evaluation (99). Results are often found to be normal in patients with diabetes who have early or small fiber predominant neuropathy.

**TABLE 3** | Summary of questionnaires available for assessing DPN.

| Questionnaire | Assessed | Type of Administration | Scoring |
|---------------|----------|------------------------|---------|
| **Symptoms**  |          |                        |         |
| NSP           | Symptoms of neuropathy | Clinician administered | 34 categories (women) |
| DNS           | Symptoms of diabetic peripheral neuropathy | Clinician administered | 36 categories (men) |
| NSS           | Symptoms of neuropathy | Clinician administered | 4 for Symptoms (Total 4) |
| NPQ           | Symptoms of neuropathic pain | Completed by the patient | 8 for muscle weakness |
| NPSI          | Symptoms of neuropathic pain | Completed by patient | 5 for sensory disturbances |
| McGill Pain Questionnaire | Multidimensional symptoms of pain | Clinician administered | 4 for autonomic symptoms (Total 17) |
| CNE           | Signs of peripheral neuropathy | Clinician administered | Total of 12 |
| **Signs**     |          |                        |         |
| NDS           | Signs of peripheral neuropathy | Clinician administered | 2 for vibration sensation |
| DNE           | Signs of peripheral neuropathy | Clinician administered | 2 for temperature sensation |
| NIS-LL        | Signs of neuropathy in the lower limbs | Clinician administered | 2 for pinprick |
| MNDS          | Signs of peripheral neuropathy | Clinician administered | 4 for ankle reflex (Total 10) |
| UENS          | Signs of peripheral neuropathy | Clinician administered | 2 for temperature sensation |
| **Symptoms and Signs** |          |                        |         |
| DN4           | Symptoms and signs of neuropathic pain | Clinician administered | 2 for pinprick (Total 22) |
| LANSS         | Symptoms and signs of neuropathic pain | Clinician administered | 3 for signs (Total 10) |
| TCNS          | Signs and symptoms of peripheral neuropathy | Clinician administered | 5 for symptoms (Total 7) |
| MNSI          | Signs and symptoms of peripheral neuropathy | Symptoms by patient | 5 for sensory tests (Total 19) |

NSP, Neuropathy Symptoms Profile; NPQ, Neuropathic Pain Questionnaire; DNS, Diabetic Neuropathy Symptom; NSS, Neuropathy Symptom Score; NPSI, Neuropathic Pain Symptom Inventory; CNE, Clinical Neurological Examination; NDS, Neuropathy Disability Score; DNE, Diabetic Neuropathy Examination; NIS-LL, Neuropathy Impairment Score in the Lower Limbs; MNDS, Michigan Neuropathy Disability Score; UENS, Utah Early Neuropathy Scale; DN4, Douleur Neuropathique en 4; LANSS, Leeds Assessment of Neuropathic Symptoms and Signs; TCNS, Toronto Clinical Neuropathy Score; MNSI, Michigan Neuropathy Screening Instrument (47, 77–86).

**DPNCheck**

To overcome some of the shortcomings of standard NCS testing, a novel point-of-care nerve conduction device (POCD), DPN-Check (Neurometrix Inc., Waltham, MA) has been developed with the potential to serve as an acceptable proxy to standard...
NCS which are time-consuming, expensive, and often require patients to be seen in specialist clinics (Figure 1C). This test for sural nerve conduction velocity and amplitude is much quicker (3 minutes) to perform than conventional electrodiagnostic testing. It has been validated in type 1 and 2 diabetes populations through comparison with the Neuropathy Disability Score (NDS) (55) and standard NCS (53, 54). These studies have reported a high sensitivity of 92-95% for detecting abnormalities (Table 4). However, these studies’ cohorts have been small, with two of the three studies assessing very low numbers of patients with type 1 diabetes (53, 54, 108). Furthermore, the DPNCheck device is dependent on the presence of an accessible sural nerve which can be anatomically absent in up to 9% of healthy subjects (55).

Small Fiber Tests

Punch Skin Biopsy
The evidence strongly suggests that in DPN, damage to small fibers precedes damage to large fibers (109, 110) and punch skin biopsy is currently considered the gold-standard single test for diagnosing small fiber neuropathy (111). A measure of intra-epidermal nerve fiber density (IENFD) can be quantified from these biopsies, which is a method of documenting the density of terminal branches of peripheral nerves within the epidermis (no/mm²). The European Federation of Neurological Societies has published guidelines for its use in diagnosing peripheral neuropathies (112) (Figure 11).

Two immuno-staining methods have become the most widely used in IENFD measurement: indirect immunofluorescence (IF) and bright-field immunohistochemistry (BFI). Although IF is considered a slightly more sensitive technique due to higher signal/noise ratio (113), the two methods have excellent correlation (114), and both can comparably detect SNF (113). At present, age-related normative values exist only for BFI, published by a multi-national group of 8 centers (115).

For both IF and BFI techniques, IENFs are typically counted directly through an epifluorescence microscope’s oculars by focusing through the optical planes (113). For IF only, the more precise, but time-consuming technique confocal microscopy (CM) can analyze optical sections of 3-dimensional images using computer software (113). The two techniques have shown excellent correlation (113), and the latter is usually used when the more complex, second-level analysis is needed.

IENFD measurements have been shown to detect small fiber neuropathy with depletion of IENFD detected in patients with normal NCS and no clinical signs or symptoms of neuropathy (59, 60). A recent study reported low sensitivity of just 61% when using a cut off of 4.5fibers/mm IENFD to diagnose clinical DPN in T1DM patients (100). Earlier studies have published significantly higher values for sensitivity (80%) (116) and specificity (95%) (117), however, these studies were comparing healthy controls to DPN patients rather than the test’s ability to identify DPN in a diabetic cohort. Other studies have found a decrease in IENFD correlating with the progression of neuropathy and duration of diabetes (118, 119) with reports that IENFD may also be lower in patients with painful DPN compared to painless DPN (120).

A 5-year follow-up study investigating the progression of DPN in T1DM and T2DM, reported a significant reduction of IENFD in T2DM patients, with IENFD measurement being the single most abnormal parameter (121). Overall, the reduction in IENFD was not significant in T1DM subjects. However, the lower number of patients in the T1DM group may explain this finding, as this would make it more challenging to prove statistically significant changes (121).

The main issue with IENFD measurements as a biomarker for small fiber neuropathy is that it is an invasive procedure. Obtaining a biopsy can cause side effects such as a mild infection due to improper wound management or, less commonly, excessive bleeding. Even though reported side effects are rare (1.9/1000) (115), the nature of this technique limits its practical use, particularly when a repeat biopsy is required in longitudinal studies or clinical intervention trials.

From a screening perspective, although intra-epidermal nerve fiber density measurement from a lower-limb skin biopsy is considered the gold standard for the diagnosis of small fiber neuropathy, it is invasive and therefore not suitable for routine screening (111, 122).

Quantitative Sudomotor Axon Reflex Test QSART
The assessment of sudomotor nerve (sweat) function has also been used to assess small autonomic c-fibers, as anhidrosis can be characteristic of the presence of peripheral autonomic neuropathy.

The reference standard for measuring sudomotor function is the quantitative sudomotor axon re-test (QSART). This test uses local sweat production, measured as a change of relative humidity over time, during and after skin activation. Special

### TABLE 4 | Summary studies for validity for four potential screening tests for DPN.

| Test       | Fibers Assessed | Validated Against | Sensitivity   | Specificity   |
|------------|-----------------|-------------------|---------------|--------------|
| DPNCheck   | Large (Aβ-fibers) | NCS               | 92-95%        | 82-89%       |
| Neuropad   | Small (C-fibers) | NCS, NDS, VPT     | 70-97.8%      | 50-67%       |
| Sudoscan   | Small (C-fibers) | NCS, Clinical Examination, UENS, VPT, NSS | 70-87.5% | 53-92% |
| CCM        | Small (A8 and C-fibers) | NCS, Clinical Examination,CASS | 59-86%(CNFL) | 61-84%(CNFL) |
|            |                 |                   | 65-82%(CNFD) | 41-79%(CNFD) |
|            |                 |                   | 17-100%(CNBD) | 45-96%(CNBD) |
software is used to digitalise, plot and analyze the temporal resolution, latency, magnitude and duration of the sudomotor response (123). However, due to highly technical demands and relative discomfort of the examination, QSART remains mostly limited to research centres and is not considered a potential screening tool for DPN (76).

Neuropad

Neuropad® is a patented 10-minute screening test for the early detection of diabetic foot syndrome and can be used as a triage test (124). It is a unique, non-invasive, painless and simple diagnostic screening test employing a chemical reaction to minute quantities of sweat as a biomarker for much earlier signs of DPN.

The test has been created to assess the sweat function (small autonomic c-fibers) in the feet of patients with suspected neuropathy. An adhesive pad containing cobalt salts is stuck onto the foot’s plantar aspect and changes color from blue to pink within 10 minutes if the sudomotor function is normal (67). If there is a decreased function, the pad remains blue or turns patchy in color. There is a strong association between skin dryness, sudomotor dysfunction and diabetic foot ulcer and the function of Neuropad. An abnormal Neuropad response is associated with sympathetic dysfunction and clinical neuropathy (Figure 1H).

This test’s main advantage is that patients can self-administer at home, reducing clinical contact time and aiming to reinforce abnormal results visually. Instructions have been confirmed as clear for patients to follow, and the test is easy to use for most patients (64). However, due to older age, visual and kinetic problems, a fifth of patients still needed help when self-testing.

It has been reported as having good to excellent (70-97.8%) (64–69) sensitivity for DPN detection (Table 4). When comparing Neuropad to a range of different small and large fiber diagnostic tests, strong correlation between Neuropad and NDS (64, 69), IENFD (65), CCM (125), Sudoscan (126) and measures of sweat gland dysfunction (127) have been reported. It has also been identified as a useful tool for staging the severity of neuropathy in patients with type 2 diabetes demonstrating excellent agreement with the Michigan classification system (128). Another significant advantage of Neuropad is its high NPV, making it ideal to serve as a screening test primarily to exclude DPN (68, 129, 130).

However, studies are not consistent in terms of the position of the Neuropad on the foot and the NDS cut-off value chosen to indicate clinical DPN presence. Furthermore, some studies graded the Neuropad color change as a percentage (66) or score out of 1 (65), whereas others simply classified the results as normal or abnormal (64, 67). Standardization of elapsed time before test result analysis is also necessary as extending the observation period to 15 minutes may provide greater diagnostic usefulness (131). This highlights a need for software development that can consistently grade each test’s color change over time to enable continuous and more accurate monitoring of sudomotor dysfunction.

In order to address these issues and increase both the sensitivity and particularly the specificity of Neuropad screening and create a continuous output, a smartphone software app and internet based image processing system has been developed. Neurometrics-Diab™ is a digital therapeutics (DTx) smartphone app which uses the Neuropad™ as a biomarker to produce a continuous record of a person’s neuropathy to see if it is improving, is stable or is worsening with trend-lines helping to predict outcomes. Using a smartphone camera, patients can take a photo of their test result which is then automatically sent to a web server where the photo is run through a proprietary image processing algorithm resulting in a percentage score which is recorded. Over time a trend can be calculated. The DTx app is currently at the advanced prototype stage. Versions for other medical conditions are under development.

Sudoscan

Sudoscan™ (Impeto Medical) is another quick, simple and non-invasive test that aims to assess sudomotor function using ‘reverse iontophoresis’ (132, 133) to measure electrochemical skin conductance (ESC) of sweat in the hands and feet. Compared to age-corrected standard data, a reduced ESC result may indicate degeneration of small c-fibers that innervate the sweat glands and, therefore, lead to reduced sweat gland function (71) (Figure 1G).

The ESC measurements from the feet are considered more sensitive for the detection of DPN than the hands (72), with less variation in results (134). This is likely due to a fluctuation in the hands’ contact on the electrodes. In contrast, the feet are aided by gravity to maintain constant pressure on the electrodes throughout the test. Lower electrochemical skin conductance at the feet was also significantly associated with increasing symptoms in a large cohort of patients with T2DM (135).

Reference values in healthy subjects are available from a global collaborative analysis comparing different ethnic groups, age, and gender (136). This study noted a significantly lower hands and feet ESC for African-American, Indian, and Chinese populations than the Caucasian population, highlighting the need to match ethnicity groups in electrochemical skin conductance studies. The same study also observed no significant difference between women and men at the hands or feet and a weak decline in ESC with increased age.

ESC measurements may also be associated with subjects’ weight (137), perhaps due to a weight-dependent change in sensitivity of the stainless-steel electrodes, or sweat gland density, when the subject is in the standing position. This could also be due to the correlation between higher weight and larger feet only (137). These hypotheses are yet to be assessed; however, these studies’ findings emphasize the importance of profile matching different subject groups for a weight that did not occur in some validation studies (71, 74).

Validation studies have reported consistently good values for sensitivity (70-87.5%) (Table 4) when using foot ESC results to screen for DPN (70–72, 74, 132). However, there are inconsistencies in the ESC cut-off values used for identifying sudomotor dysfunction, ranging from 52uS (70) to 77uS (72). This variation and inconsistencies in the neuropathy tests being used as a reference standard are the likely cause of the extensive
range in reported specificity of between 53-92% (70–72, 74). It highlights the need for standardization of the classification criteria used. Patient cohorts also differed in their severity of DPN, with participants in one study (74) having significantly more advanced DPN than those in the study by Smith and colleagues (71). Therefore the test performed better in the former.

Overall, Sudoscan appears to be a promising DPN screening test that is non-invasive, easy to perform and eliminates the subjective component of clinician error, demonstrating good correlation with IENFD (137). However, there is some doubt as the current evidence does not strongly support ESC to distinguish between patients with DPN and control individuals (138). Therefore, longitudinal and more extensive cohort validation studies are needed, along with standardization of diagnostic criteria before Sudoscan can be used as a screening tool for small fiber neuropathy.

It is evident that progress has been made in developing point of care devices (POCDs) which may be capable of diagnosing DPN early before clinical signs are apparent. Neuprod, DPNChek and Sudoscan are newer screening tests that have demonstrated potential for early detection, however validation studies, thus far, have reported a range of sensitivities, specificities depending on cohort and test used for comparison (Table 3).

**Quantitative Sensory Testing (QST)**

Quantitative sensory testing (QST) has become a common method for evaluating small nerve fiber function using thermal threshold and thermal pain measurements and large fiber function using vibration thresholds (52). The most common commercial system is the Medoc TSA-II NeuroSensory Analyzer (Medoc Advanced Medical Systems, Israel) which is used to determine thermal thresholds, (Figure 1F). In recent years a cheaper, more portable device has been designed, NerveCheck (Phil Med Europe S.L., Barcelona, Spain), which has shown good reproducibility (ICC values = 0.79, 0.71 and 0.86 for vibration, warm and cold sensation respectively) and comparable diagnostic accuracy (86%, 72% and 79% for vibration, warm and cold sensation testing respectively) to established QST equipment for the diagnosis of DPN (139).

Cold thresholds can be used to evaluate myelinated A-delta fiber function, whereas warm thresholds are used to assess the function of unmyelinated C-fibers. Published normative data sets are available for heat threshold detection (140–145), and recommendations for conducting QST in both clinical practice and research have previously been published by The International Association for the Study of Pain (NeuPSIG) (146).

QST has been found to have reasonable repeatability (50); however, inter-operator and inter-patient variability depend on several factors. Training of both examiner and patient, the methodology of assessment, baseline skin temperature, stimulus characteristics, location and number of stimuli sites and duration of intervals between tests have all affected QST measurements (52). Using standardized methodology with extensive training has significantly reduced interobserver variability (147, 148). However, this may be too time-consuming to be implemented.

When it comes to the effects of body fat on thermal detection thresholds, there are conflicting findings. Malmström et al. (149) failed to detect differences between obese and other groups for cold and warm thresholds at the supraclavicular site (149). In contrast, Pycke and colleagues (150) found that obese participants had significantly higher cold and warm detection thresholds than normal BMI participants on the abdomen.

Two psychophysical algorithms can be used to determine thermal thresholds. These are the method of limits and the method of level (described in detail elsewhere (50, 151), with the method of limits used more commonly due to it being less time-consuming (146). Measurements determined using limits have been reported as significantly higher than those measured by Level, irrespective of test location (52). However, the two methods correlate well with each other (52) and the 2013 consensus concluded that both were reliable (146). The major difference between these two methods is the effect of reaction time. For the method of limits, a patient has a longer reaction time due to age or height (causing a more extended sensory pathway) which may erroneously give a higher threshold.

Both warm and cold thresholds can be affected in patients with DPN, irrespective of how long the course of diabetes is, but the frequency of abnormal warm thresholds is significantly higher (141). A study found that cold detection thresholds significantly reduced in DM patients with no evidence of pre-clinical, sub-clinical and clinical DPN, respectively (152). A longitudinal study also found a significant positive correlation between deterioration of cold detection thresholds and pain intensity in painful DN, with warm detection thresholds also correlating at non-significant value (153).

One major issue with the use of QST is that it cannot differentiate between peripheral and central temperature perception causes. It involves sensory receptors, spinal cord pathways and termination sites in the thalamus. This means that if there is poor concentration, a language barrier or cognitive defect, subjects’ results may affect their subjective nature (51).

**CORNEAL NERVES AS A BIOMARKER FOR DPN**

Anatomically and developmentally, the eye can be considered an extension of the central nervous system (CNS). The cornea is the most densely innervated tissue in the body. It is richly supplied by a large number of sensory nerve fibers and a lesser number of autonomic fibers (154). The cornea possesses small unmyelinated C-fibers and myelinated Aβ-fibers for sensory innervation. These are derived from the trigeminal nerve’s ophthalmic division and enter the corneal stroma at its periphery, in a radial fashion parallel to the corneal surface. As the fibers run forward toward the cornea center, they lose their myelin sheath; a necessary step to maintain corneal transparency (154).
Corneal C-fibers form a delicate three-dimensional network known as the 'sub-basal nerve plexus' (155), which is located beneath the basal layer of the corneal epithelium. Mapping of the cornea (156) has shown that this plexus forms a spiral or 'whorl like' pattern. The spiral center, often called the vortex, is located approximately 2-3 mm inferior and nasal to humans' corneal apex. Due to this arrangement, sub-basal nerves in the superior and human apical cornea are oriented vertically. In contrast, sub-basal nerves in other corneal regions may be oriented horizontally or obliquely, consistent with their locations within the whorl-like plexus (157).

Corneal confocal microscopy (CCM) is a non-invasive, **in vivo** ophthalmic imaging technique that allows a detailed examination of the cornea, at high magnification, on a cellular level (**Figure 1J**) (158). By capturing multiple two-dimensional images at different depths, CCM imaging can delineate the corneal layers of the cornea (158), providing superior magnification compared to standard slit-lamp biomicroscopy. These properties allow CCM to acquire high-quality images of the corneal C-fibers in the sub-basal nerve plexus. Considering the known relationship between damage to these fibers and diabetic peripheral neuropathy, the potential for their use as a surrogate biomarker for DPN has been identified.

When analyzing the sub-basal nerve plexus, most studies report results from four morphological parameters: Corneal nerve fiber density (CNFD) which is the total number of main nerve fibers per mm², corneal nerve fiber length (CNFL) which is the sum of the length of all nerve fibers and branches (mm/mm²), tortuosity coefficient (TC) which is a unitless measurement that uses deviation from a straight line to measure the tortuosity of the main nerve fibers independent of their orientation, and corneal nerve branch density (CNBD) which is defined as the number of branches emanating from all main nerve fibers. There is, however, a discrepancy in how this can be quantified between studies with the established protocol for these parameters described elsewhere (62).

Of these four parameters, CNFL has been the most frequently used parameter for DPN, with one study reporting superior reliability than other parameters (159). Some studies have assessed the diagnostic performance of CCM for DPN and reported the results for CNFL only (101, 105). Hertz et al. (159) reported that CNFL produced the highest intra-observer and inter-observer reproducibility (ICC of 0.72 and 0.73 respectively), with TC demonstrating the lowest (0.23 and 0.29 respectively).

Two other parameters that have been reported in research studies are nerve reflectivity (160) and nerve fiber beading (number/100 µm) (161, 162). Nerve fiber reflectivity is usually assessed using grades as first outlined by Oliveira-Soto and Efron (160), whereby classification can be split into four grades according to a comparison with reference images. The number of beadings is defined as the number of beadings in a length of 100um of sub-basal nerves within a frame (163). Both parameters have demonstrated changes in dry eye conditions, where patients with Sjögren’s syndrome have demonstrated significantly higher beading than dry eye patients of other primary causes (164). However, both measures require subjective judgment. Beading can be challenging to quantify and may require special software and may have poor repeatability and reproducibility (163).

More recently, newer corneal parameters have been investigated. These include inferior whorl length (IWUL) (165) defined as the length of the nerves at the inferior whorl of the superficial nerve plexus, nerve fiber width (166) and nerve fiber area (167). These new measures have previously shown significant differences between the non-neuropathic and clinically neuropathic groups in DM (168) with CNFW and CNFA, demonstrating 74% and 66% sensitivity-specificity equal error rate point, respectively when identifying non-neuropathic patients compared to control subjects (168). This indicates that these new measures may have the capacity to identify individuals with early neuropathy; however, research into these new parameters is currently limited.

Another type of cell found in the sub-basal layer and has been of interest in DPN research are dendritic cells. These antigen-presenting cells of the cornea are of paramount importance. They play a critical role in activating other immune systems in the ocular surface, influencing both suppression and induction of inflammation (169, 170).

Langerhans cells are usually up to 15µm in diameter and can be seen in various forms (171). In their immature form, these cells have small dendritic processes or lack dendrites completely and are mainly located in the peripheral cornea’s epithelium (172). In pathological states, Langerhans cells mature, form interlocking dendritic processes which may comprise a net-like structure, and migrate from the periphery into the central cornea (172).

Cross-sectional studies have shown an increase in the densities of Langerhans cells in the central cornea related to conditions such as dry eye with and without contact lens wear (171, 173) bacterial keratitis (174), thyroid eye disease (175) and diabetes (176, 177).

**CCM for the Detection of DPN**

In the early 2000s, a novel study by Rosenberg and colleagues reported the correlation between increasing severity of DPN, corneal sensitivity and progressive loss of corneal sub-basal nerve fibers (178). This was closely followed by a similar small study published in 2003 (179) which found that CCM was able to detect abnormalities in the corneal nerves of 18 patients with diabetes deemed to have only mild neuropathy using conventional tests. Similarly, Midena and colleagues (180) reported a significant decrease in corneal nerve fiber and branch number, along with decreased beading in patients with diabetes. It should be noted that these three studies used a light corneal confocal microscope, which is the first commercially available generation of the confocal imaging device with inferior image quality in comparison to the methods now commonly used.

Since then, the use of corneal confocal microscopy (CCM) for rapid, noninvasive clinical assessment of corneal nerves has grown substantially, especially in recent years. It has proven to be particularly useful as a diagnostic marker for detecting...
diabetic neuropathy and a range of other peripheral neuropathies (62, 100–106, 181–186). Some of them are reviewed in this paper.

**Diagnostic Performance for Clinical DPN**

Several cross-sectional studies have evaluated the ability of CCM to diagnose clinical levels of DPN in comparison to a range of other diagnostic tests (Table 5). It must be noted that most of these studies assessed patients with T1DM only, meaning there is limited published data available for the diagnostic sensitivity and specificity values when assessing patients with T2DM.

These studies used a cut-off point for the reference neuropathy test/combination of tests to determine whether a patient had a DPN. However, the reference test and cut-off points varied between studies meaning there were no universal diagnostic reference criteria. Some studies validated CCM against a single test of nerve conduction studies (NCS) (100, 101) or neuropathy disability score (NDS) (62). In contrast, other studies used a combination of the two (102) or NCS and clinical examination (104, 106). A combination of diagnostic tests will likely increase the efficiency of detecting DPN compared to one test used alone. This is significant as some studies compare CCM to one single test, which is not the gold standard in the case of NDS. NCS only measures large fiber function, which is affected later than small nerve fibers in DPN. One study (187), demonstrated that diagnostic ability of CNFL measurement in DM patients is significantly worse if using clinical signs and symptoms as a reference standard in comparison to electrophysiology, plus one sign/symptom as per the Toronto consensus guidelines, which highlights the importance of a standardized diagnostic reference (187).

To explore which of the many measurements derived from CCM could best distinguish patients with and without clinical DPN, as part of each study, the same patients were examined using CCM, and all nerve parameters were derived. For each nerve parameters tested, ROC curves were plotted to determine a CCM cut-off point used to distinguish between patients with and without DPN in the diabetic cohort only. A range of cut-off points was studied to identify the best sensitivity/specificity value for diagnosing DPN for each nerve parameter.

CNFL was the most commonly reported nerve parameter for these studies, with all nine assessing its diagnostic ability and finding significant differences between patients with and without DPN. A range of sensitivity values between 59 and 86% was found and a specificity range of 61-84%, depending on the cut-off value used for diagnosis. The earliest of these studies (62), examined patients using a Tomey confoscan CCM. It is well known that these images are of more inferior quality, making it more challenging to identify nerve fibers during analysis. This is likely the explanation for the significantly lower diagnostic threshold value reported in this study compared to the others presented (Table 5).

For corneal nerve fiber density (CNFD) six of the cross-sectional studies (Table 5) reported a significant reduction in DM patients with DPN compared to both DM patients without DPN and healthy controls (62, 100, 102, 104, 106, 107). These studies reported sensitivity and specificity ranges as 65-82% and 41-79% respectively. A significantly higher cut off point of 39.2 CNFD no/mm² was defined in T2DM patients in the consortium study, resulting in an increased sensitivity value to 69% (104). This may explain why its specificity is the lowest value of only 41%, as a higher cut-off value may create more false-positive results. It is notable that based on their cohort, Scarr et al. (106) defined the lowest thresholds for diagnosis for both CNFD and CNFL out of the studies using the Heidelberg retinal tomograph (HRT) (III) CCM. This is likely due to their significantly older-aged cohort compared to the other cross-sectional studies as CNFD and CNFL have been shown to reduce with age (188).

For corneal nerve branch density (CNBD), six cross-sectional studies (62, 100, 102, 104, 106, 107) reported a significant reduction in DM with DPN than without DPN. For diagnostic value, the sensitivity (17-100%) (62, 102) and specificity (45-96%) (62, 102) values were significantly more varied, suggesting that this parameter has shown the least promise for DPN diagnosis until now.

There are several strengths to each of the cross-sectional studies. Three used profile-matched healthy controls (101, 102, 106), meaning that differences in measurements between the two groups due to age should have been accounted for, giving a better representation of changes that have occurred due to DPN. Ahmed et al. (101) also looked at the option of combining two corneal nerve parameters for the identification of neuropathy. Two of the studies looked at both manual, and automated software for DPN diagnosis (102, 106) which is significant as automated software for analysis would be required if CCM were to be introduced in large-scale screening.

Perkins et al. (104) in a consortium multi-center study funded by NIH assessed data from a large cohort of 998 subjects. This large cohort of different ethnicities and T1DM and T2DM gave a more accurate representation of the population of people with diabetes instead of focusing on one specific sub-group. Another strength of this NIH funded study was that it suggested an alternative approach of using one lower value chosen to more confidently rule in the presence of neuropathy (maximize specificity) and one higher value determined to simultaneously, more confidently rule out the presence of neuropathy (maximize sensitivity). This combination of decision criteria aims to minimize false positive and negative results. The study found that using this criterion increased their sensitivity to 88% and specificity to 89% using manual methods of analysis. However, this method caused 57.8% of the subjects to be unclassified as they fell between the two limits.

There were several limitations to these cross-sectional studies. Some did not match the clinical profiles of their patients to the control subjects. For example, the patients’ group in Alam et al. (100) being significantly older, with significantly longer disease duration than the T2DM group without neuropathy. Another limitation of two of these studies (101, 106) was that only 1 image per eye was used for analysis. One criterion for choosing this image in the Ahmed et al. (101) study was the most nervous frame. Using this method to choose 1 image per eye instead of calculating an average of 3 images or more may be less time
| Study | Number subjects | Type of CCM device | Diabetes Type | Age (years) | Disease Duration (years) | Type of Neuropathy | Validated Against | Sensitivity (%) | Specificity (%) | CNFL Threshold (mm/mm²) | CNFD Threshold (no./mm²) | CNBD Threshold (no./mm²) | CNFT (TC) |
|-------|-----------------|-------------------|---------------|-------------|-------------------------|---------------------|------------------|----------------|---------------|----------------------|----------------------|----------------------|-----------|
| Cross-sectional Tavakoli et al. (62) | 118 (101 DM, 17 HC) | Tomey ConfoScan P4 | 1,2 | 55 ± 4.8 (HC) | 10.7 ± 1.82 (DPN-) 15.5 ± 2.08 (Mild DPN) 18.6 ± 3.06 (Mod DPN) 19.3 ± 2.85 (Sev DPN) | DSPN | NDS | 64 (CNFL) | 79 (CNFL) | 3.39 | 27.81 | 13.89 | – |
| Ahmed et al. (101) | 153 (89 DM, 63 HC) | HRT (II) | 1 | 38.9 ± 17.6 (HC) | 17.6 ± 14.0 (DPN-) 31.4 ± 13.5 (DPN+) | DSPN | NOS, Clinical Examination | 85 | 84 | 14 | – | – | – |
| Tavakoli et al. (107) | 52 (34 DM, 18 HC) | HRT (III) | 1,2 | 42 ± 0 (DAN-) 44 ± 3 (DAN+) | 12 ± 3 (DAN-) 26 ± 2 (DAN+) | DAN | Composite autonomic scoring scale (CASS) | 86 (CNFL) | 78 (CNFL) | 4.8 | 23.3 | 19.5 | – |
| Chen et al. (102) | 89 (63 DM, 26 HC) | HRT (III) | 1 | 44 ± 15 (HC) 44 ± 13 (DNP-) 59 ± 11 (DNP+) | 23 ± 16 (DPN-) 39 ± 14 (DPN+) | DSPN | NCS, DNS/NDs | 59 (CNFL) | 74 (CNFL) | 16.5 | 24 | 15 | – |
| Alam et al. (100) | 88 (61 DM, 27 HC) | HRT (III) | 1 | 41 ± 114.9 (HC) 38.8 ± 12.5 (DNP-) 53.3 ± 11.9 (DNP+) | 17.2 ± 12.0 (DPN-) 37.2 ± 13.1 (DPN+) | DSPN | NCS, Clinical Examination | 74 (CNFL) | 79 (CNFL) | 16.8 | 25 | 36.5 | – |
| Scarr et al. (106) | 137 (67DM, 69HC) | HRT(III) | 1 | 64 ± 8 (HCs) 65 ± 7 (T1DM) | 52-58 (Median 54) | DSPN | NCS, Clinical Examination | 73 (CNFL) | 75 (CNFL) | 13.7 | 18.8 | 15.6 | – |

(Continued)
TABLE 5 | Continued

| Study Number | Type of Diabetes | Age (years) | Disease Duration (years) | Type of Neuropathy | Disease Type | Type of CCM device | Number of subjects | Longitudinal Pritchard 90% HRT | CNFL Threshold \( (\mu \text{m} / \text{mm}) \) | CNFD Threshold \( (\mu \text{m} / \text{mm}^2) \) | CNBD Threshold \( (\mu \text{m} / \text{mm}^2) \) | CNFT Threshold \( (\mu \text{m} / \text{mm}^2) \) | Sensitivity (\%) | Specificity (\%) |
|--------------|-----------------|-------------|--------------------------|-------------------|-------------|-------------------|-------------------|-----------------------------|------------------|------------------|------------------|------------------|-----------------|-----------------|-----------------|
| 998 Tomey et al. (104) | 1 | 42 ± 19 | 21 ± 15 | DSPN | NCS, Clinical Examination | CCM | 11 | 90 | 95 | 93 | 92 | 87 | 57 | 67 |
| 105 | 2 | 62 ± 10 | 12 ± 9 | DSPN | NCS, DNSSD, NDS | Confoscan Examination | 1 | 90 | 95 | 93 | 92 | 87 | 57 | 67 |
| 106 | 1 | 42 ± 16 | 15 ± 12 | DSPN | NCS, TCNS | Longitudinal Pritchard (T1DM) | 11 | 90 | 95 | 93 | 92 | 87 | 57 | 67 |
| 103 | 1 | 34 ± 15 | 17 ± 12 | DSPN | NCS, DNSSD, NDS | Confoscan Examination | 1 | 90 | 95 | 93 | 92 | 87 | 57 | 67 |

Studies presented are all published studies. Data presented as standard units or mean ± standard deviation.

As there are currently no therapeutic agents approved for DPN treatment, early detection is essential to modify any risk factors. Several studies have specifically investigated CCM findings in early stages of DM and mild levels of DPN.

The published baseline characteristics of T1DM patients as part of the LANDMark study (189) were that corneal nerve fiber length was reduced in patients without clinical neuropathy, based on the Toronto criteria. Another paper written from the same study (190) assessed the use of CCM for distinguishing between control patients and DM patients (156 T1DM, 75 T2DM) with and without clinical DPN. For the patients with DPN, all cases were defined as mild (as defined by QST plus neurophysiology). This study reported a significant reduction in CNFL when comparing patients with and without mild neuropathy, suggesting that CNFL changes may occur early in the course of the disease.

One study (191) assessed the corneal sub-basal plexus in patients with recently diagnosed T2DM (mean duration 2.1 ± 1.6 years). This study reported significant differences between CNFD, CNBD and CNFL parameters when comparing the patient cohort to the control group, with CNFD emerging as the most sensitive in detecting corneal nerve pathology; indeed 21% of the patients fell below the 2.5th percentile of the control group. For this study, high-adapted software produced an image composed of an image stack. It reconstructed a combined mosaic image with an expanded field of view compared to standard imaging using CCM. This software is also able to correct for artefacts. As this method is not widely used, there is no direct comparison to other studies. To our knowledge, no other studies are assessing recently diagnosed patients with DM (<2 years duration). It must also be considered that in this study, even though patients were diagnosed newly, there may have been a delay in diagnosis, which could have varied between patients.

Another study assessing early nerve changes assessed patients with impaired glucose tolerance (IGT) (192). This study reported evidence that CCM may detect changes in nerve parameters before established diabetes. They reported that in patients with IGT, CNFD and CNBD were significantly reduced with 40.5% of subjects with IGT having significant small-fiber damage based on CNFD reduction compared to control subjects. This agreed with a decrease in IENFD and significantly higher warm thresholds and vibration perception thresholds in the same cohort (192).
Langerhans Cells in DPN

The dominant antigen-presenting cells in the cornea and ocular surfaces are Langerhans cells (LCs) and Dendritic cells (DCs) which are derived from the bone marrow and can stimulate both primary and secondary T and B-cell responses (169). It has been shown that Corneal confocal microscopy provides a non-invasive means to readily demonstrate Langerhans cells (LCs) in the cornea of healthy subjects and a range of inflammatory ophthalmic conditions (Figure 2) (174, 193). Some studies demonstrated that the number of LCs increases in Diabetic Neuropathy (177, 194–196); however, the LCs activation mechanism is still unclear.

Zhivov et al. (176) assessed the corneal basal epithelial layer and the sub-basal nerve plexus for the presence of LCs in healthy subjects and found that 31% of subjects had LCs present. Tavakoli and colleagues (177) were the first to assess Langerhans cell density with differing severities of diabetic neuropathy (based on NDS scoring compared to controls). This study found a significant increase in the proportion of individuals with LCs in patients with T1DM and T2DM (73.8%) compared to control subjects (46.1%). The study also found that LC density was significantly increased in the patients with diabetes (17.73 ± 1.45) compared to control subjects (6.94 ± 1.58). However, with progression of neuropathy, patients with moderate and severe neuropathy showed a reduction in the LC density in comparison to patients with mild neuropathy and were not significantly different from control subjects. This may suggest that LCs have a role in the early phase of nerve damage. This study only focused on Bowman’s layer which has been shown to have a lower density of LCs in comparison to the epithelial layer (197), so is not an accurate representation of overall LC density in the central cornea. Another limitation of the study was that the Tomey Confoscan CCM was used for imaging which has been shown to underestimate LCs density compared to newer the Heidelberg HRT III CCM (176) and cannot differentiate mature from immature LCs.

A more recent study, used the HRT (III) CCM to assess the density of LCs in a cohort of children and adolescents with diabetes and found a higher percentage of patients (85.9%) and controls (69.1%) with LCs present when compared to the previous two studies (176, 177). This study was also able to distinguish between mature and immature cells by classing LCs of less than 50 µm in length, without dendritic structures as immature cells and those greater than 50 µm with dendritic structures as mature cells. A significant increase in mature and immature cells was found, and a correlation existed between CNFD and LCs density (198). However, this study only assessed a specific age-group of the diabetic cohort, so it does not represent the whole diabetic population. Overall, studies investigating LCs density in patients with diabetes are still limited, and more information is required to conclude the effect of diabetes on LCs.

Comparing CCM and IENFD

Studies have found CCM to be comparable with measures of IENFD from biopsies in their diagnostic performance for detecting patients with clinical levels of DPN (100, 102) (Figure 3). Both studies found no significant difference in their diagnostic efficacy in patients with T1DM.

An older study using the Tomoscan confocal microscope (110) also concluded that both IENFD and CCM assessment accurately quantify small nerve fiber damage in patients with diabetes. Intraepidermal and corneal nerve fiber lengths were also both further reduced in patients with painful compared with painless diabetic neuropathy.

In comparison, one study’s findings, using HRT (III) CCM were notably different (191). This study reported that CCM and IENFD were both able to detect nerve fiber loss in recently diagnosed type 2 diabetes, but mainly in different patients. They, therefore, suggested a possible patchy manifestation pattern of small fiber neuropathy. Only 2.7% of the patients had both abnormal CNFD and IENFD. Abnormal CCM with normal IEND was noted in 20.5% of the diabetic group and 11.0% for vice versa. No correlation between the CCM measures and IENFD was observed. There are possible explanations for these contradictory findings. Firstly, the cohort of patients in this study was all patients with T2DM, all of who had been newly diagnosed (known diabetes duration of ≤ 1 year). The disease duration was significantly less than that of Chen et al. (102) (DPN+ 39 ± 14 DPN- 23 ± 15 years) and Alam et al. (100) (DSPN+ 37.2 ± 13.1

---

**FIGURE 2** | Images from Bowman’s layer of the cornea at (A) T2DM with mild neuropathy; (B) moderate neuropathy; (C) Healthy Control Subject (yellow arrows show LCs and red arrows indicates main corneal nerve c nerve fibers).
DSPN - 17.2 ± 12.0 years). These two studies also used comparisons between patients with and without clinical DPN to compare IENFD and CCM, whereas Ziegler et al. (191) only compared patients with T2DM to healthy controls. Lastly, Ziegler et al. used a different location for the IENFD biopsy. This was taken from the lateral calf in comparison to the dorsum of the foot. This more proximal site may have been at less risk of IENFD changes or may present a different pattern of loss, as DSPN is known to follow a distal-proximal course.

One issue with the comparison of IENFD with analysis of the corneal sub-basal nerve plexus is that intra-epidermal nerves consist of both unmyelinated C-fibers (90%) and myelinated A-delta fibers (10%) (199), which are both included in the measurement for IENFD. In contrast, the sub-basal nerve plexus is made up of C-fibers only. This means that a direct comparison cannot be made between the two measurements. Although the A-delta fibers only make up 10% of the total number in the epidermal layer, they may be affected differently in DPN than the unmyelinated C-fibers, affecting the overall results.

**Longitudinal Studies for Application of CCM for Assessment DPN**

Longitudinal studies suggest that CCM has good predictive value for subsequent DPN (187, 200). Longitudinal analysis of a T1DM cohort showed a mean 1-year change in CNFL was -1.6% in patients with unstable T1DM, while healthy volunteers showed a 5% increase per year (200).

As part of a 4-year follow up study, a study (103) (Table 5) found that three corneal nerve parameters were all significant predictors for the development of DPN, with a baseline CNFL of <14.9 mm/mm² being the strongest single predictor when compared to 11 other small and large fiber tests. Other studies (105, 201) also reported an association between lower baseline CNFL and DPN development. Pritchard et al. (105) (Table 5) found a significant association with longer diabetes duration, higher triglycerides, worsening retinopathy and nephropathy, impaired sensation to temperature and vibration and slower peroneal and sural nerve conduction velocities. However, studies with larger cohorts and patients with type 2 diabetes are needed to confirm these studies’ findings and a more extended period of monitoring. Studies should also ensure a set number of follow-ups over a set period as for Lovblom et al. (103) more than half of the patients had just one follow up visit, meaning that true progression is statistically challenging to prove.

Another prospective study specifically looked at a group of patients with IGT (202). They found that in subjects with IGT, lower baseline CNFD, CNBD, CNFL, and lower mean dendritic length of IENF were the strongest predictors of progression to T2DM over three years. Although significance was not recorded, there appeared to be very similar baseline HbA1c measures between those patients who remained IGT vs those developing T2DM over the three years follow up (42.8 ± 1.2 and 42.4 ± 1.0 respectively (mmol/mol), suggesting that corneal nerve fibers may have been stronger predictors of conversion to T2DM in comparison to baseline HbA1c. Those subjects who returned to normoglycemia showed a significant improvement in their CCM parameters while IENF length continued to decline during the same period. These findings may suggest that corneal nerve fibers regenerate quicker than IENF when glycemic control is improved.

Another observational follow up study (203), examined a small cohort of patients with diabetes (15 T1DM and 10 T2DM) at baseline and follow-up at two years. At follow up, an
improvement in glycemic control, cholesterol levels and blood pressure were found and increased CNFD, with a significant correlation between a decrease in HbA1c and CNFD. This demonstrated that improvements in HbA1c might lead to morphological repair of corneal nerve fibers, however, due to the small sample size and mixing of T1DM and T2DM in analysis, it is unclear if these differences are occurring in both types. It must also be noted that this was not planned as an interventional study, meaning there were no placebo controls or randomization, which would need to take place to confirm or reject these findings.

CCM has been used to investigate the sub-basal nerve plexus in patients with T1DM post-simultaneous pancreas and Kidney (SPK) transplant. Tavakoli et al. (186) assessed 15 patients at 6 and 12 months SPK transplant and found a significant improvement in all CCM parameters at 12 months. Symptoms, neurophysiology, quantitative sensory testing and skin biopsy results remained unchanged in the same patients. A similar, earlier study using an older CCM model also reported similar findings, with CNFD and CNFL increasing significantly after just six months (204). These studies may demonstrate that CCM can provide a novel non-invasive means to evidence early nerve repair missed by currently advocated assessment techniques. However, an alternative interpretation of this data could be that corneal nerves respond well to the restoration of insulin and normoglycemia. In contrast, other peripheral nerves do not; therefore, CCM may be measuring something unique that is not an accurate biomarker of the condition of peripheral nerves.

**CCM Application in Clinical Trials**

Several DPN intervention trials have focused on large fiber function and have generally had ineffective outcomes. More recently, some studies have instead focused on CCM measures as markers for clinical trials of potential new treatments. In a recent pilot trial of seal oil omega-3, polyunsaturated fatty acid supplementation in patients with type 1 diabetes (disease duration 27 ± 14 years) over 12 months (205), there was a significant increase (30.4%) in corneal nerve fiber length, with no change found in NCS velocity or sensory function. Those subjects at high risk for future DPN and those with already diagnosed DPN (as determined by a Toronto clinical neuropathy score of ≥ 1) showed the best treatment response. This study was a single-arm, open-label, proof of concept trial; therefore, no placebo group was used, which is necessary to reduce a trial’s bias.

Another study to determine whether the peptide, ARA 290, improves metabolic control and neuropathic pain in patients with type 2 diabetes used CCM measurements as a co-primary endpoint. This study found that ARA 290 treatment was associated with an increase in corneal nerve fiber density correlated with changes in neuropathic symptoms (206). This study was a double-blind, placebo-controlled investigator-initiated phase II clinical trial whose inclusion criteria were patients with T2DM who also had small fiber neuropathy symptoms. Whether allocation to the treatment and placebo groups was randomized was not discussed in the article. This study’s limitation was that patients assigned to both groups generally had excellent metabolic control (HbA1c = 7.3 ± 0.4 and 6.9 ± 0.2 for treatment and placebo groups respectively), which does not truly represent the clinical population of patients with T2DM. It may be that this treatment is less or more effective for patients with poor metabolic control, comparatively. Finally, disease duration was also not mentioned, so it was unclear if there was a significant difference between the two groups.

These trials may be evidence that, like small fiber damage occurring before large fiber damage, small fibers are also the first to start regenerating after damage. Trials over a longer period, including other small fiber neuropathy measures, are required before these findings can be confirmed.

**CONCLUSIONS**

There is an un-met need for a simple, reliable and accurate test for the early detection of diabetic peripheral neuropathy (DPN) which may help reduce the incidence of ulcers and amputations in people with diabetes which remains at an all-time high and increases by between 25-20% per annum. Current tests for DPN in primary care require HCPs to conduct and detect late neuropathy. Many people with diabetes do not have an annual foot check despite it being one of the most important of the 8 care processes mandated by NICE. In fact over 500,000 people in England alone never have an annual diabetes related foot examination. This places them at risk of having a first presentation with an active foot ulcer in A&E. Early diagnosis of DPN is critical since early damage to the small nerve fibers in the feet of people with diabetes can be stopped from progressing and even reversed while late signs of DPN and in particular lack of vital protective sensation in the feet cannot be reversed. Although a common and much feared complication, over 30% of people with diabetes remain unaware.

Diabetes UK consistently state that 80% of diabetes related foot complications are preventable yet no practical solution to this huge problem has been proposed. The only primary care test recommended by the National Institute of Health and Care Excellence (NICE) is the 10g Semmes Weinstein monofilament examination (SWME) which is a crude, inaccurate and subjective test for lack of sensation in the feet of people with diabetes - defined as ‘late neuropathy’ which cannot be reversed. Its evidence base is poor and outside NICE it is regarded as a particularly poor test for DPN.

Early diagnosis and timely intervention are thus essential in preventing its development. Whereas measurement of urinary albumin excretion and fundoscopic examinations serve as objective tests for early nephropathy and retinopathy respectively, a comparably objective, accurate test which is unbiased by the patient’s subjective response is lacking for DPN.

Currently advocated diagnostic tests either focus on large nerve fibers, thus are not sensitive to early abnormalities, are too time-consuming and/or are too invasive to be used for repeated measures.

More recently, a number of non-invasive tests have been developed as surrogate measures of DPN. Of these, CCM has
shown great potential for the detection of small fiber neuropathy, the earliest manifestation of DPN. CCM has also demonstrated promising prognostic utility and has demonstrated early nerve regeneration post-SPK surgery and as part of several clinical trials.

Given that CCM is a rapid and non-invasive test, it is suitable for large-scale screening for DPN, and advancements in automated analysis software would further improve its promising potential.

In conclusion, there is no optimal biomarker and ideal endpoint available for DPN at the current time. Hence, there is an urgent need to identify the most accurate early biomarker of nerve damage to diagnose DPN in patients’ clinical care better and, in particular, to permit a precise evaluation of future therapies in clinical trials. The global effort among scientists and clinicians, and researchers in the field should address these shortcomings to reduce incidence of complications and to achieve this; the search should continue for better and sensitive biomarkers to reduce incidence of complications and to achieve this; the search should continue for better and sensitive tests, screening, and early detection. We need to improve our systematic evaluation of the evidence and promote—from each translational step to the next—the biomarkers with the best evidence and performance at different populations. This will require evaluation of the wider biomarker research agenda. Such evaluation may also benefit more from fostering international collaborations rather than from the fragmented efforts of small, opportunistic studies. “We must learn to measure what we value rather than valuing what we can easily measure”.

AUTHOR CONTRIBUTIONS

JC wrote and revised the manuscript. HF, FI, and AS reviewed and revised the paper. MT designed, conceived the study, wrote the major revision and made comments, had full access to all data, and is the guarantor. MT and AS supervised JC. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

The authors thank the Exeter NIHR Clinical Research Facility for support. Special thanks to Ptolemaios Sarrianni, Consultant in Clinical Neurophysiology for providing the NCS images and Mr. John Simpson for providing Neuropad images.

REFERENCES

1. Neeland IJ, Patel KV. Chapter 4 - Diabetes: Key Markers of Injury and Prognosis. In: V Nambi, editor. Biomarkers in Cardiovascular Disease. Netherlands: Elsevier (2019), p. 41–51.
2. Internation Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation (2019). Available at: https://diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html.
3. Diabetes UK. Us, diabetes and a lot of facts and stats. London, UK: Diabetes UK (2019). Available at: https://www.diabetes.org.uk/resources-s3/2019-02/1362B_Facts%20and%20stats%20update%20jan%202019_LOW%20RES_EXTERNAL.pdf.
4. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Carr Diabetes Rep* (2019) 19(10):86. doi: 10.1007/s11892-019-12112-8
5. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care* (2017) 40(1):136. doi: 10.2337/dc16-2042
6. Sloan G, Shillo P, Selvarajah D, Wu J, Wilkinson ID, Tracey I, et al. A new look at painful diabetic neuropathy. *Diabetes Res Clin Pract* (2018) 144:177–91. doi: 10.1016/j.diabres.2018.08.020
7. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. *Diabetes Care* (2010) 33(5):1090–6. doi: 10.2337/dc09-1941
8. Kioski K, Scott W, Winkle K, Kylakos S, McCracken LM. Psychosocial Factors in Painful Diabetic Neuropathy: A Systematic Review of Treatment Trials and Survey Studies. *Pain Med* (2019) 20(9):1756–73. doi: 10.1093/pm/pnz071
9. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *Jama* (2005) 293(2):217–28. doi: 10.1001/jama.293.2.217
10. Ndipl A, Ebah I, Mbako A. Neuropathic diabetic foot ulcers - evidence-to-practice. *Int J Gen Med* (2012) 5:129–34. doi: 10.2147/IJGM.S10328
11. Smith BE. Chapter 3 - Focal and entrapment neuropathies. In: DW Zochodne, editor. *Handbook of Clinical Neurology*, vol. 126. Amsterdam, Netherlands: Elsevier (2014), p. 31–43.

12. National Institute for Health and Care Excellence (NICE). *Diabetic foot problems: prevention and management*. London, UK: NICE (2015). Available at: https://www.nice.org.uk/guidance/ng19.
13. Thorud JC, Piemmons B, Buckley CJ, Shibuya N, Jupiter DC. Mortality After Nontraumatic Major Amputation Among Patients With Diabetes and Peripheral Vascular Disease: A Systematic Review. *J Ankle Surg* (2016) 55(3):591–9. doi: 10.1053/j.jfas.2016.01.012
14. Manzano GM, Giuliano LMP, Nóbrega JAM. A brief historical note on the classification of nerve fibers. *Arquivos Neuro Psiquiatria* (2008) 66:117–9. doi: 10.1590/S0004-282X2008000100033
15. Gregg EW, Gu Q, Williams D, de Rijke M, Cheng YJ, Geiss L, et al. Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older. *Diabetes Res Clin Pract* (2007) 77(3):485–8. doi: 10.1016/j.diabres.2007.01.005
16. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. *N Engl J Med* (2005) 352(4):341–50. doi: 10.1056/NEJMoa032782
17. Martin CL, Albers JW, Pop-Busui R. Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. *Diabetes Care* (2014) 37(1):51–8. doi: 10.2337/dc13-2114
18. Trota D, Verrotti A, Galladini C, Chiarelli F. Diabetic neuropathy in children and adolescents. *Pediatr Diabetes* (2004) 5(1):44–57. doi: 10.1111/j.1399-543X.2004.00041.x
19. Solders G, Thalme B, Aguirre-Aquino M, Brandt L, Berg U, Persson A. Nerve conduction and autonomic nerve function in diabetic children. A 10-year follow-up study. *Acta Paediatrica* (1997) 86(4):361–6. doi: 10.1111/j.1651-2227.1997.tb09023.x
20. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Cohen RM, et al. Effect of baseline pain score on the ACCORD randomized trial. *Lancet* (2010) 376(9739):419-20. doi: 10.1016/S0140-6736(10)60576-4
21. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Vascular risk factors and diabetic complications in veterans with type 2 diabetes. *N Engl J Med* (2009) 360(2):129–39. doi: 10.1056/NEJMoa0808431
22. Jende JME, Groener JB, Oikonomou D, Heiland S, Kopf S, Pham M, et al. Diabetic neuropathy differs between type 1 and type 2 diabetes: Insights from magnetic resonance neurography. *Ann Neurol* (2018) 83(3):588–98. doi: 10.1002/ana.25182
Carmichael et al. Advances in Diagnosis of Diabetic Neuropathy

31. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 358(6):580–91. doi: 10.1056/NEJMoa0706245

32. Ziegler D, Behler M, Schroers-Teuber M, Roden M. Near-normoglycaemia and long-term glycemic control are linked to peripheral innervation in people with diabetic peripheral neuropathy. Cardiopulm Pharmacol Ther (2020) 19(1):102. doi: 10.1155/2020/6568559

33. Kluding PM, Asnoum M, Singh R, Jernigan S, Farmer K, Rucker J, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications (2012) 26(5):424–9. doi: 10.1016/j.jdiacomp.2012.05.007

34. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle Intervention for Pre-Diabetic Neuropathy. Diabetes Care (2006) 29(2):321–7. doi: 10.2337/dci05-0014

35. Ishibashi F, Taniguchi M, Kosaka A, Uetake H, Tavakoli M. Improvement in glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The ADDITION-Denmark Diabetes Care (2018) 41(5):1068–75. doi: 10.2337/dc17-2062

36. Abbott CA, Garrow AP, Carrington AL, Morris J, Van Ross ER, Boulton AJ. Foot Ulcer Risk Is Lower in South-Asian and African-Caribbean Compared With European Diabetic Patients in the UK. Diabetes Care (2005) 28(8):1869–75. doi: 10.2337/diacare.28.8.1869

37. Fadavi H, Tavakoli M, Foden P, Ferdoussi M, Metropolis IN, Jezioriska M, et al. Explanations for less small fibre neuropathy in South Asian versus European subjects with type 2 diabetes in the UK. Diabetes/Metab Res Rev (2018) 34(7):e3044. doi: 10.1002/dmrr.3044

38. Zhou Z, Sun B, Huang S, Zhu C, Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovasc Diabetol (2020) 19(1):102. doi: 10.1186/s12933-020-01085-6

39. Bakker K, Apelqvist J, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev (2012) 28(Suppl 1):S135–s1. doi: 10.2337/dc12-0011

40. Yang Z, Zhang Y, Chen R, Huang Y, Ji L, Sun F, et al. Simple tests to screen for diabetic peripheral neuropathy. Cochrane Database Syst Rev (2018) 7: CD010975. doi: 10.1002/14651858.CD010975.pub2

41. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempley P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care (2010) 33(10):2285–93. doi: 10.2337/dc10-1303
Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. PloS One (2015) 10(11):e0142309. doi: 10.1371/journal.pone.0142309

Tavakkol M, Quattrini C, Abbott C, Kallinkos P, Marshall A, Finnigan J, et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care (2010) 33 (8):1792–7. doi: 10.2337/dc10-0253

Tavakkol M, Malik RA. Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. J Visualized Experiments: JoVE (2011) (47):2194. doi: 10.3791/2194

Tentoulouris N, Achtidis V, Marinou K, Katsilambros N. Evaluation of the Self-Administered Indicator Plaster Neuropad for the Diagnosis of Neuropathy in Diabetes. Diabetes Care (2008) 31(2):236. doi: 10.2337/dc07-1942

Quattrini C, Tavakoli M, Tavakoli M, Begum P, Boulton AJM, Malik RA. The Neuropad test: a visual indicator test for human diabetic neuropathy. Diabetologia (2008) 51(6):1046–50. doi: 10.1007/s00125-008-0987-y

Ponirakis G, Petropoulos IN, Fadavi H, Alam U, Asghar O, Marshall A, et al. The diagnostic accuracy of Neuropad for assessing large and small fibre diabetic neuropathy. Diabet Med J Br Diabet Assoc (2014) 31(12):1673–80. doi: 10.1111/dme.12536

Papanas N, Papathodorou K, Christakidis D, Papazoglou D, Giassakis G, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, et al. The diagnostic accuracy of Neuropad for assessing large and small fibre diabetic neuropathy. Diabet Med J Br Diabet Assoc (2014) 31(12):1673–80. doi: 10.1111/dme.12536

Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR. The diagnostic accuracy of Neuropad for assessing large and small fibre diabetic neuropathy. Diabet Med J Br Diabet Assoc (2014) 31(12):1673–80. doi: 10.1111/dme.12536

Krieger S-M, Reimann M, Haase R, Henkel E, Hanefeld M, Ziemssen T. Selvarajah D, Cash T, Davies J, Sankar A, Rao G, Grieg M, et al. The diagnostic accuracy of Neuropad for assessing large and small fibre diabetic neuropathy. Diabetes Care (2010) 33(12):236. doi: 10.2337/dc10-0253

Kamenov ZA, Petrova ZA, Marinou K, Katsilambros N, Sardić M, Begum P, Boulton AJM, Malik RA. The Neuropad test: a visual indicator test for human diabetic neuropathy. Diabetologia (2008) 51(6):1046–50. doi: 10.1007/s00125-008-0987-y

Selvarajah D, Cash T, Davies J, Sankar A, Rao G, Grieg M, et al. The diagnostic accuracy of Neuropad for assessing large and small fibre diabetic neuropathy. Diabet Med J Br Diabet Assoc (2014) 31(12):1673–80. doi: 10.1111/dme.12536

Bril V, Tomoška S, Buchanan RA, Perkins BA. Group mS. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabetes Med (2009) 26(3):240–6. doi: 10.1111/j.1464-5491.2009.02657.x

Gupta H, Jin RH, Nguyen HQ, McCann MT, Unser M. CNN-Based Projected Gradient Descent for Consistent CT Image Reconstruction. IEEE Trans Med Imaging (2018) 37(6):1440–53. doi: 10.1109/TMI.2018.2832656

Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short-Form 36 Bodily Pain Scale (SF–36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOP). Arthritis Care Res (Hoboken) (2011) 63 Suppl 11:5240–52. doi: 10.1002/acr.20543

Herman WH, Pop-Busui R, Braunflieth BH, Martin CL, Cleary PA, Albers JW, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabetes Med (2012) 29(7):937–44. doi: 10.1111/j.1464-5491.2012.03644.x

Meijer J-WG, Bosma E, Lefrandt JD, Links TP, Smit AJ, Stewart RE, et al. Clinical Diagnosis of Diabetic Polyneuropathy With The Diabetic Neuropathy Symptom and Diabetic Neuropathy Examination Scores. Diabetes Care (2003) 26(3):697. doi: 10.2337/diabetes.26.3.697

Meijer JW, van Sonderen E, Blaauwweide EL, Smit AJ, Groothoff JW, Eisma WH, et al. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care (2000) 23 (6):750–3. doi: 10.2337/diabetes.23.6.750

Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfaia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabetes Med (2012) 29(5):578–85. doi: 10.1111/j.1464-5491.2011.03500.x

Asad A, Hameed MA, Khan UA, Ahmed N, Butt MU. Reliability of the neurological scores for assessment of sensorimotor neuropathy in type 2 diabetics. J Pak Med Assoc (2010) 60(3):166–70.

Melzack R, Katz J. The McGill Pain Questionnaire: Appraisal and current status. In: Handbook of pain assessment, 2nd ed. New York, NY, US: The Guilford Press (2001). p. 35–52.

Melzack R. The short-form McGill Pain Questionnaire. Pain (1987) 30 (2):191–7. doi: 10.1016/0304-3959(87)91074-8

Dyck PJ, Sherman WR, Hallett LM, John Service F, O’Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol (1980) 6(5):590–6. doi: 10.1002/ana.40008068

Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Grifﬁths J, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabetes Med (2002) 19(5):377–84. doi: 10.1002/diab.10371

Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care (2002) 25(11):2048–52. doi: 10.2337/diabetes.25.11.2048

Moghadderi A, Bakhshiour P, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosci (2016) 6(5):77–81. doi: 10.1016/j.clineuro.2015.08.003

Weisman A, Bril V, Ngo M, Lovblom LE, Halpern EM, Orzag A, et al. Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. PloS One (2013) 8(3):e58783. doi: 10.1371/journal.pone.0058783

Litchy WJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, et al. Proficiency of nerve conduction using standard methods and reference values (CI. NPhys Trial 4). Muscle Nerve (2014) 50(6):900–8. doi: 10.1002/mus.24243

Wahren J, Foxt H, Daniels M, Arezzo JC. Long-Acting C- and P-Peptide and Neurropathy in Type 1 Diabetes: A 12-Month Clinical Trial. Diabetes Care (2013) 36(4):596–602. doi: 10.2337/dc12-2068

Ruggenenti P, Lauria G, Iervi JP, Fassi A, Ileva R, Rota S, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (2011) 58(5):776–83. doi: 10.1161/HYPERTENSIONAHA.111.174474
Mayaudon H, Miloche PO, Bauduceau B. A new simple method for assessing sudomotor function: Relevance in type 2 diabetes. *Diabetes Metab* (2010) 36 (6, Part 1):450–4. doi: 10.1016/j.diabet.2010.05.004

Gin H, Baudoin R, Raafatien CH, Rigalleau V, Gonzalez C. Non-invasive and quantitative assessment of sudomotor function for peripheral diabetic neuropathy evaluation. *Diabetes Metab* (2011) 37(6):527–32. doi: 10.1016/j.diabet.2011.05.003

Bordier L, Dolz M, Monteiro L, Névoret M-L, Calvet J-H, Bauduceau B. Accuracy of a Rapid and Non-Invasive Method for the Assessment of Small Fiber Neuropathy Based on Measurement of Electrochemical Skin Conductances. *Front Endocrinol* (2016) 7:7–18. doi: 10.3389/fendo.2016.00018

Mao F, Liu S, Qiao X, Zheng H, Xiong Q, Wen J, et al. Sudoscan is an effective screening method for asymptomatic diabetic neuropathy in Chinese type 2 diabetes mellitus patients. *J Diabetes Investig* (2017) 8(3):363–8. doi: 10.1111/jdi.12575

Vinik AI, Smith AG, Singleton JR, Callaghan B, Freedman BI, Tuomilehto J, et al. Normative Values for Electrochemical Skin Conductances and Impact of Ethnicity on Quantitative Assessment of Sudomotor Function. *Diabetes Technol Ther* (2016) 18(6):391–8. doi: 10.1089/dia.2015.0396

Novak P. Electrochemical Skin Conductance Correlates with Skin Nerve Fiber Density. *Front Aging Neurosci* (2016) 8:199. doi: 10.3389/fnagi.2016.00199

Bordier L, Campagnolo M, Callaghan B, Gibbons CH. Sudomotor function: it does really make matter sudomotor function? *Clin Autonomic Res* (2019) 29(1):31–9. doi: 10.1007/s10286-018-0540-0

Ponirakis G, Odriozola MN, Odriozola S, Petropoulos IN, Azmi S, Fadavi H, et al. Greater corneal nerve loss at the inferior whorl is related to the presence of diabetic neuropathy and painful diabetic neuropathy. *Sci Rep* (2018) 8:1532. doi: 10.1038/s41598-018-21643-x

Tavakoli M, Petropoulos IN, Malik RA. Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot. *J Diabetes Sci Technol* (2013) 7(5):1179–89. doi: 10.1177/193229681300700509

Tavakoli M, Hossain P, Malik RA. Clinical applications of corneal confocal microscopy. *Clin Ophthalmol (Auckland NZ)* (2008) 2(2):435–45. doi: 10.2147/OPHT.S1490

Hertz P, Bril V, Orszag A, Ahmed A, Ng E, Nwe P, et al. Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. *Diabetes Med* (2011) 28(10):1253–60. doi: 10.1111/j.1464-5491.2011.03299.x

Oliveira-Soto L, Efron N. Morphology of corneal nerves using confocal microscopy. *Cornea* (2001) 20(4):374–8. doi: 10.1097/00003226-200105000-00008

Maddaloni E, Sabatino F, Del Toro R, Crugliano S, Grande S, Lauria Pantono A, et al. In vivo corneal confocal microscopy as a novel non-invasive tool to investigate cardiac autonomic neuropathy in Type 1 diabetes. *Diabetes Med* (2015) 32(2):262–6. doi: 10.1111/dme.12583

Ishibashi F, Kojima R, Taniguchi M, Kosaka A, Uetake H, Tavakoli M. The Expanded Bead Size of Corneal C-Nerve Fibers Visualized by Corneal Confocal Microscopy Is Associated with Slow Conduction Velocity of the Peripheral Nerves in Patients with Type 2 Diabetes Mellitus. *J Diabetes Res* (2016) 7:1. doi: 10.1155/2016/3653459

Labbé A, Alwawi H, Van Went C, Brusno E, Georgescu D, Bauduin C. The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease. *Invest Ophthalmol Vis Sci* (2012) 53(8):4926–31. doi: 10.1167/iovs.11-8708

del Castillo JM, Wasfy MAS, Fernandez C, Garcia-Sanchez J. An In Vivo Confocal Masked Study on Corneal Epithelium and Subbasal Nerves in Patients with Dry Eye. *Invest Ophthalmol Vis Sci* (2004) 45(9):3030–5. doi: 10.1167/iovs.2004-0251

Petropoulos IN, Ferdoussi M, Marshall A, Alam U, Ponirakis G, Azmi S, et al. The Inferior Whorl For Detecting Diabetic Peripheral Neuropathy Using Corneal Confocal Microscopy. *Invest Ophthalmol Vis Sci* (2015) 56 (4):2498–504. doi: 10.1167/iovs.14-15919

Kowtharapu BS, Winter K, Marfurt C, Allgeier S, Kohler B, Hovakimyan M, et al. Comparative quantitative assessment of the human cornea sub-basal nerve plexus by in vivo confocal microscopy and histological staining. *Eye (Lond)* (2017) 31(3):481–90. doi: 10.1038/eye.2016.220

Brines M, Culver DA, Ferdoussi M, Tamemaat MR, van Velzen D, Dahan A, et al. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. *Sci Rep* (2018) 8(1). doi: 10.1038/s41598-018-23107-w

Chen X, Graham J, Dabbah MA, Petropoulos IN, Tavakoli M, Malik RA. An Automatic Tool for Quantification of Nerve Fibers in Confo
transplantation in patients with type 1 diabetes. *Diabetes Care* (2007) 30 (10):2608–12. doi: 10.2337/dc07-0870

205. Lewis EJH, Perkins BA, Lovbloom LE, Bazinet RP, Wolever TMS, Bril V. Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. *Neurology* (2017) 88(24):2294–301. doi: 10.1212/WNL.0000000000004033

206. Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson C-G, Kirk RI, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. *Mol Med (Cambridge Mass)* (2015) 20(1):658–66. doi: 10.2119/molmed.2014.00215

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Carmichael, Fadavi, Ishibashi, Shore and Tavakoli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
## GLOSSARY

| Acronym | Definition |
|---------|------------|
| ACCORD | Action to Control Cardiovascular Risk in Diabetes |
| ACE     | Angiotensin-Converting Enzyme |
| BFI     | Bright Field Immunohistochemistry |
| BMI     | Body Mass Index |
| CCM     | Corneal Confocal Microscopy |
| CNBD    | Corneal Nerve Branch Density |
| CNFA    | Corneal Nerve Fiber Area |
| CNFD    | Corneal Nerve Fiber Density |
| CNFL    | Corneal Nerve Fiber Length |
| CNFW    | Corneal Nerve Fiber Width |
| CNS     | Central Nervous System |
| CTBD    | Corneal Total Branch Density |
| DAN     | Diabetic Autonomic Neuropathy |
| DN4     | Douleur Neuropathique en 4 |
| DNE     | Diabetic Neuropathy Examination |
| DNS     | Diabetic Neuropathy Score |
| DPN     | Diabetic Peripheral Neuropathy |
| DSPN    | Distal Symmetrical Polynephopathy |
| EDIC    | Epidemiology of Diabetes Interventions and Complications |
| ESC     | Electrochemical Skin Conductance |
| HbA1c   | Glycated Hemoglobin |
| HDL     | High-Density Lipoprotein |
| HES     | Hospital Eye Service |
| HRT     | Heidelberg Retinal Tomograph |
| IENFD   | Intra-epidermal Nerve Fiber Density |
| IF      | Indirect Immunofluorescence |
| IGT     | Impaired Glucose Tolerance |
| IWL     | Inferior Whorl Length |
| LANSS   | Leeds Assessment of Neuropathic Symptoms and Signs |
| LC      | Langerhans Cell |
| LDL     | Low-Density Lipoprotein |
| MNDs    | Michigan Neuropathy Disability Score |
| MNSI    | Michigan Neuropathy Screening Instrument |
| MRI     | Magnetic Resonance Imaging |
| MTHFR   | Methylenetetrahydrofolate Reductase |
| NCS     | Nerve Conduction Studies |
| NDS     | Neuropathy Disability Score |
| NeuPSIG | International Association for the Study of Pain |
| NEURODIAB | Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes |
| NIS-LL  | Neuropathy Impairment Score in the Lower Limbs |
| NPO     | Neuropathic Pain Questionnaire |
| NPV     | Negative Predictive Value |
| NPSI    | Neuropathic Pain Symptom Inventory |
| NSS     | Neuropathy Symptoms Score |
| QSART   | Quantitative Sudomotor Axon Testing |
| QST     | Quantitative Sensory Testing |
| SPN     | Small Fiber Neuropathy |
| T1DM    | Type 1 Diabetes Mellitus |
| T2DM    | Type 2 Diabetes Mellitus |
| TC      | Tortuosity Coefficient |
| TCNS    | Toronto Clinical Neuropathy Score |
| UEENS   | Utah Early Neuropathy Scale |